Your browser doesn't support javascript.
Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19.
Jeyaraman, Madhan; John, Albin; Koshy, Santhosh; Ranjan, Rajni; Anudeep, Talagavadi Channaiah; Jain, Rashmi; Swati, Kumari; Jha, Niraj Kumar; Sharma, Ankur; Kesari, Kavindra Kumar; Prakash, Anand; Nand, Parma; Jha, Saurabh Kumar; Reddy, P Hemachandra.
  • Jeyaraman M; Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.
  • John A; Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street/MS/9410/4B 207, Lubbock, TX 79430, United States of America.
  • Koshy S; Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street/MS/9410/4B 207, Lubbock, TX 79430, United States of America.
  • Ranjan R; Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Anudeep TC; Department of Plastic Surgery, Topiwala National Medical College and BYL Nair Ch. Hospital, Mumbai, Maharashtra, India.
  • Jain R; School of Medical Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Swati K; Department of Biotechnology, School of Life Science, Mahatma Gandhi Central University, Motihari, Bihar, India.
  • Jha NK; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Sharma A; Department of Life Science, School of Basic Science and Research, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Kesari KK; Department of Applied Physics, School of Science, Aalto University, Espoo, Finland.
  • Prakash A; Department of Biotechnology, School of Life Science, Mahatma Gandhi Central University, Motihari, Bihar, India.
  • Nand P; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India.
  • Jha SK; Department of Biotechnology, School of Engineering & Technology, Sharda University, Greater Noida, Uttar Pradesh, India. Electronic address: saurabh.jha@sharda.ac.in.
  • Reddy PH; Internal Medicine, Neuroscience/Pharmacology, Neurology, Public Health Departments and School of Health Professions, Texas Tech University Health Sciences Center, 3601 4th Street/MS/9410/4B 207, Lubbock, TX 79430, United States of America. Electronic address: hemachandra.reddy@ttuhsc.edu.
Biochim Biophys Acta Mol Basis Dis ; 1867(2): 166014, 2021 02 01.
Article in English | MEDLINE | ID: covidwho-938765
ABSTRACT
The coronavirus disease 2019 (COVID-19) has been threatening the globe since the end of November 2019. The disease revealed cracks in the health care system as health care providers across the world were left without guidelines on definitive usage of pharmaceutical agents or vaccines. The World Health Organization (WHO) declared COVID-19 as a pandemic on the 11th of March 2020. Individuals with underlying systemic disorders have reported complications, such as cytokine storms, when infected with the virus. As the number of positive cases and the death toll across the globe continue to rise, various researchers have turned to cell based therapy using stem cells to combat COVID-19. The field of stem cells and regenerative medicine has provided a paradigm shift in treating a disease with minimally invasive techniques that provides maximal clinical and functional outcome for patients. With the available evidence of immunomodulatory and immune-privilege actions, mesenchymal stem cells (MSCs) can repair, regenerate and remodulate the native homeostasis of pulmonary parenchyma with improved pulmonary compliance. This article revolves around the usage of novel MSCs therapy for combating COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Mesenchymal Stem Cell Transplantation / Pandemics / Mesenchymal Stem Cells / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Biochim Biophys Acta Mol Basis Dis Year: 2021 Document Type: Article Affiliation country: J.bbadis.2020.166014

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Mesenchymal Stem Cell Transplantation / Pandemics / Mesenchymal Stem Cells / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Female / Humans / Male Language: English Journal: Biochim Biophys Acta Mol Basis Dis Year: 2021 Document Type: Article Affiliation country: J.bbadis.2020.166014